Skip to main content
SpringerLink
Log in

Expression of the p53 protein in malignant melanomas as a prognostic indicator

  • Original Paper
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

It is currently widely accepted that the tumour suppressor gene p53 is critically involved in the proliferation and differentiation of tumour cells including melanoma cells. In the present study, we examined 60 cases of primary melanoma to compare the expression of p53 protein with conventional prognostic markers for melanoma such as clinical and histological parameters. No correlation was found between the p53 protein and clinical factors except for the presence of a metastatic node and development to clinical stage II. However, the expression of p53 protein was significantly associated with tumour thickness over 1.5 mm, levels IV and V of invasion, the presence of ulceration, and high mitotic rate for 5-year survival rate. Although many questions still remain to be answered, our results and those of others for various other malignant tumours, implicate p53 in malignant transformation of pigment cells. Indeed, it could be a new marker for an unfavourable prognosis of malignant melanoma, even though the gene mutation in this highly lethal tumour has yet to be established.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H (1994) Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 73: 629–636

    PubMed  Google Scholar 

  2. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GAD-D45 is defective in ataxia-telangiectasia. Cell 71: 587–597

    PubMed  Google Scholar 

  3. Harris AL (1991) Cancer genes: telling changes of base. Nature 350: 377–378

    PubMed  Google Scholar 

  4. Mclaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC (1992) The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66: 735–738

    PubMed  Google Scholar 

  5. McGregor JM, Yu CC-W, Dublin EA, Barnes DM, Levison DA, Macdonald DM (1993) P53 immunoreactivity in human malignant melanoma and dysplastic nevi. Br J Dermatol 128: 606–611

    PubMed  Google Scholar 

  6. Yamamoto M, Takahashi H (1993) Immunohistochemical detection of the p53 oncoprotein in tumours of melanocytic origin. Virchows Archiv [A] 422: 127–132

    Google Scholar 

  7. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP (1991) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6: 1699–1703

    PubMed  Google Scholar 

  8. Balch CM, Soong S-j, Shaw HM, Milton GW (1985) An analysis of prognostic factors in 4000 patients with cutaneous melanoma. In: Balch CM, Milton GW (eds) Cutaneous melanoma. Clinical management and treatment results worldwide. JB Lippincott, Philadelphia, pp 321–352

    Google Scholar 

  9. Balch CM (1981) A multifactorial analysis of melanoma. III. Prognostic factors in melanoma patients with lymph node metastases (Stage II). Ann Surg 193: 377–388

    PubMed  Google Scholar 

  10. Day CL Jr, Mihm MC Jr, Lew RA, Harris MN, Kopf AW, Fitzpatrick TB, Harrist TJ, Golomb FM, Postel A, Hennesey P, Gumport SL, Raker JW, Malt RA, Cosimi AB, Wood WC, Roses DF, Gorstein F, Rigel D, Friedman RJ, Mintzis MM, Sober AJ (1982) Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51–3.99 cm). A conceptual model for tumor growth and metastasis. Ann Surg 195: 35–43

    PubMed  Google Scholar 

  11. Milton GW, Shaw HN, Farago GA, McCarthy WH (1980) Tumor thickness and the site time of first recurrence in cutaneous malignant melanoma (Stage 1). Br J Surg 67: 543–546

    PubMed  Google Scholar 

  12. Breslow A (1970) Thickness, cross-sectional areas, and depth of invasion of the prognosis of cutaneous melanoma. Ann Surg 172: 902–908

    PubMed  Google Scholar 

  13. Clark WH Jr, From L, Bernardino EA, Mihm MC (1969) The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29: 705–726

    PubMed  Google Scholar 

  14. McGovern VJ, Mihm MC Jr, Bailly C, Booth JC, Clark WH Jr, Cochran AJ, Hardy EG, Hicks JD, Levene A, Lewis MG, Little JH, Milton GW (1973) The classification of malignant melanoma and its histologic reporting. Cancer 32: 1446–1458

    PubMed  Google Scholar 

  15. Balch CM, Murad TM, Soong S-J, Ingalls AL, Halpern NB, Maddox WA (1978) A multifactorial analysis of melanoma: Prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 188: 732–742

    PubMed  Google Scholar 

  16. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK, McGuire WL (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200–206

    PubMed  Google Scholar 

  17. Sarkis A, Dalbagni G, Cordon-Cardo C, Zuo-Feng Z, Sheinfeld J, Fair WR, Herr HW, Reuter VE (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85: 53–59

    PubMed  Google Scholar 

  18. Shimaya K, Shiozaki H, Inoue M, Tahara H, Monden T, Shimano T, Mori T (1993) Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma. Virchows Archiv [A] 422: 271–276

    Google Scholar 

  19. Weiss J, Schwechheimer K, Cavenee WK, Herlyn M, Arden K (1993) Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer 54: 693–699

    PubMed  Google Scholar 

  20. Oka K, Nakano T, Arai T (1993) p53CM1 expression is not associated with prognosis in uterine cervical carcinoma. Cancer 72: 160–164

    PubMed  Google Scholar 

  21. Strech JR, Gatter KC, Ralfkiaer E, Lane DP, Harris AL (1991) Expression of mutant p53 in melanoma. Cancer Res 51: 5976–5979

    PubMed  Google Scholar 

  22. Cristofolini M, Boi S, Girlando S, Zumiani G, Cristofolini P, Palma PD, Doglioni C, Barbareschi M (1993) p53 protein expression in nevi and melanomas. Arch Dermatol 129: 739–743

    PubMed  Google Scholar 

  23. Akslen L, Morkve O (1992) Expression of p53 protein in cutaneous melanoma. Int J Cancer 52: 13–16

    PubMed  Google Scholar 

  24. Tobal K, Warren W, Cooper CS, McCartney A, Hungerford J, Lightman S (1992) Increased expression and mutation of p53 in choroidal melanoma. Br J Cancer 66: 900–904

    PubMed  Google Scholar 

  25. Castresana JS, Rubio MP, Vazquez JJ, Idoate M, Sober AJ, Seizinger BR, Barnhill RL (1993) Lack of alleric deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer 55: 562–565

    PubMed  Google Scholar 

  26. Volkenandt M, Schlegel U, Nanus DM, Albino AP (1991) Mutational analysis of human p53 gene in malignant melanoma. Pigment Cell Res 4: 35–40

    PubMed  Google Scholar 

  27. Lassam NJ, From L, Kahn HJ (1993) Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 53: 2235–2238

    PubMed  Google Scholar 

  28. Kraiss S, Quaiser A, Oren M, Monthenari M (1988) Oligomerization of oncoprotein p53. J Virol 62: 4737–4744

    PubMed  Google Scholar 

  29. Pinhashi O, Michalovits D, Ben-Zeev A, Oren M (1986) Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature 320: 182–185

    PubMed  Google Scholar 

  30. Finlay CA (1993) The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13: 301–306

    PubMed  Google Scholar 

  31. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B (1993) p53 mutation and mdm2 amplification in human soft tissue sarcomas. Cancer Res 2231–2234

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Sapporo Medical University School of Medicine, Minami 1, Nishi 16, Chuo-ku, 060, Sapporo, Japan

    Miho Yamamoto, Hiroyuki Takahashi, Kazuya Saitoh, Takashi Horikoshi & Makoto Takahashi

Authors
  1. Miho Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroyuki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuya Saitoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takashi Horikoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Makoto Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamamoto, M., Takahashi, H., Saitoh, K. et al. Expression of the p53 protein in malignant melanomas as a prognostic indicator. Arch Dermatol Res 287, 146–151 (1995). https://doi.org/10.1007/BF01262323

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01262323

Key words

Search

Navigation